In 2010, Cellectis also entered into a license agreement with Boehringer Ingelheim to obtain, breed and utilize animal models in pharmaceutical research throughout Europe, as well as with Bayer HealthCare to use its Homologous recombination patents. BASF plant sciences has also broadened its collaboration with Cellectis to utilize its tailor-made meganucleases.
Acquisition of assets from CytoPulse Inc.
Electroporation is a very efficient way of inserting molecules such as Meganucleases into any...